Genmab (CPSE:GMAB) - Cotización, noticias y análisis

Resumen de acción GMAB

Genmab A/S desarrolla terapias de anticuerpos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. Saber más

Análisis fundamental de GMAB
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	4/6
Rendimiento pasado	4/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Cotiza un 84.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 23.73%

Los beneficios aumentaron un 12.9% el pasado año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

No se han detectado riesgos en GMAB a partir de nuestros controles de riesgos.

Competidores de Genmab A/S

Bavarian Nordic

CPSE:BAVA

DKK 13.3b

H. Lundbeck

CPSE:HLUN B

DKK 42.7b

ALK-Abelló

CPSE:ALK B

DKK 34.9b

Neurocrine Biosciences

NasdaqGS:NBIX

US$11.9b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Genmab
Precios históricos de las acciones
Precio actual de la acción	DKK 1,463.50
Máximo en las últimas 52 semanas	DKK 2,283.00
Mínimo de 52 semanas	DKK 1,450.00
Beta	0.86
1Cambio en 1 mes	-6.40%
Variación en 3 meses	-19.61%
Cambio de 1 año	-34.08%
3Variación en 3 años	-44.59%
Variación en 5 años	-6.52%
Variación desde la OPV	528.11%

Noticias y actualizaciones recientes

The Price Is Right For Genmab A/S (CPH:GMAB)

Sep 19

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Aug 22

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Nov 13

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Jun 19

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

May 29

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Mar 18

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 27

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Dec 17

Rentabilidad de los accionistas

	GMAB	DK Biotechs	Mercado DK
7D	-9.0%	-11.8%	-3.1%
1Y	-34.1%	-10.0%	5.7%

Rentabilidad vs. Industria: Los resultados de GMAB fueron inferiores a los de la industria Danish Biotechs, que obtuvo un rendimiento del -10% el año pasado.

Rentabilidad vs. Mercado: GMAB obtuvo unos resultados inferiores a los del mercado Danish, que fueron del 5.7% el año pasado.

Volatilidad de los precios

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement	3.3%
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Precio estable de las acciones: GMAB no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GMAB (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	2,635	Jan G.J. de Winkel	www.genmab.com

Genmab A/S desarrolla anticuerpos terapéuticos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. La empresa comercializa DARZALEX, un anticuerpo monoclonal humano para el tratamiento de pacientes con mieloma múltiple (MM); teprotumumab para el tratamiento de la enfermedad ocular tiroidea; y Amivantamab para el cáncer gástrico o esofágico avanzado o metastásico y el CPNM. Sus productos incluyen daratumumab para tratar MM, cánceres de la sangre no MM y amiloidosis AL; GEN1047; tisotumab vedotin para tratar cánceres de cuello uterino, ovario y sólidos; DuoBody-PD-L1x4-1BB, y DuoBody-CD40x4-1BB para tratar tumores sólidos; Epcoritamab para el linfoma difuso de células B grandes y la leucemia linfocítica crónica en recaída o refractarios; y HexaBody-CD38 y GEN3017 para el tratamiento de neoplasias hematológicas.

Resumen de fundamentos de Genmab A/S

¿Cómo se comparan los beneficios e ingresos de Genmab con su capitalización de mercado?
Estadísticas fundamentales de GMAB
Capitalización bursátil	DKK 92.09b
Beneficios(TTM)	DKK 4.70b
Ingresos (TTM)	DKK 19.84b

19.8x

Ratio precio-beneficio (PE)

4.7x

Ratio precio-ventas (PS)

¿Está GMAB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GMAB
Ingresos	DKK 19.84b
Coste de los ingresos	DKK 774.00m
Beneficio bruto	DKK 19.07b
Otros gastos	DKK 14.37b
Beneficios	DKK 4.70b

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	74.03
Margen bruto	96.10%
Margen de beneficio neto	23.69%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GMAB a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GMAB

Recompensas

Análisis de riesgos

Competidores de Genmab A/S

CPSE:BAVA

DKK 13.3b

CPSE:HLUN B

DKK 42.7b

CPSE:ALK B

DKK 34.9b

NasdaqGS:NBIX

US$11.9b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind